Related Experiment Video
Updated: May 3, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
A bioinformatics pipeline for the design of a SART3-targeted cancer vaccine with enhanced immunogenicity
Zeynab Bayat1, Faezeh Mahdian-Khoo1, Lida Samie1
1Department of Oral and Maxillofacial Medicine, Faculty of Dentistry, Hamadan University of Medical Sciences, Hamadan, Iran.
Background And Objectives:
Squamous cell carcinoma antigen recognized by T-cells 3 (SART3) has emerged as a promising target for cancer immunotherapy, given its overexpression in various malignancies and low or absent expression in non-tumorous tissues. This study aimed to design rationally and in silico evaluate a multi-epitope T cell vaccine targeting SART3, incorporating a TLR4 agonist adjuvant. The vaccine's predicted immunogenicity, physicochemical properties, structural stability, and interaction with TLR4 were comprehensively assessed. Additional assessments of cytokine-inducing potential, B-cell epitopes, and disulfide engineering opportunities were also executed.
Methods:
Potential T-cell epitopes from SART3 were identified using IEDB and screened for antigenicity (VaxiJen), toxicity (ToxinPred), and MHC-I/II binding affinity. Cytokine-inducing epitopes were evaluated using IL4pred, IL-10Pred, and IFNepitope servers. B-cell epitopes were predicted using ElliPro. The vaccine underwent comprehensive physicochemical, structural (I-TASSER/GalaxyRefine), molecular docking (HDOCK), molecular dynamics simulations, and disulfide engineering (Disulfide by Design 2.0) analyses.
Results:
The optimized 344-residue vaccine demonstrated non-allergenicity, high stability (instability index 17.16), antigenicity (Vaxijen 0.67), and solubility (SOLpro 0.96). HDOCK predicted favorable vaccine-TLR4 binding (ΔG = - 265.61 kcal/mol, confidence 91%). MD simulations confirmed complex stability. Cytokine analysis revealed the potential to induce IL-4 and IL-10. The Val80-Ala123 pair exhibited the lowest bond energy (1.16 kcal/mol), indicating the optimal geometry for disulfide bond formation. The in silico immune simulations demonstrated a robust immune response following vaccine administration.
Conclusion:
This rationally designed SART3-targeted multi-epitope vaccine exhibits promising in silico characteristics across immunogenicity, physicochemical, cytokine-inducing, B-cell epitope, structural, and disulfide engineering profiles, warranting experimental validation for cancer immunotherapy development.
Insights
A novel multi-epitope vaccine targeting Squamous Cell Carcinoma Antigen Recognized by T-cells 3 (SART3) shows promise for cancer immunotherapy. In silico analysis indicates strong immunogenicity, stability, and potential for robust immune response, warranting further experimental validation.
Area of Science:
- Immunology
- Computational Biology
- Vaccine Design
Background:
- Squamous cell carcinoma antigen recognized by T-cells 3 (SART3) is overexpressed in various cancers, making it a potential target for immunotherapy.
- SART3 exhibits low or absent expression in non-tumorous tissues, suggesting a favorable safety profile for targeted therapies.
Purpose of the Study:
- To rationally design and computationally evaluate a multi-epitope T cell vaccine targeting SART3.
- To incorporate a TLR4 agonist adjuvant to enhance vaccine efficacy.
- To assess the vaccine's immunogenicity, physicochemical properties, structural stability, and interaction with TLR4.
Main Methods:
- Epitope identification and screening for antigenicity, toxicity, and MHC binding using IEDB and VaxiJen.
- Prediction of cytokine-inducing and B-cell epitopes using specialized servers.
- Comprehensive in silico analysis including structural modeling, molecular docking, molecular dynamics simulations, and disulfide engineering.
Main Results:
- The designed 344-residue vaccine demonstrated favorable non-allergenicity, high stability, antigenicity, and solubility.
- Favorable binding and stable complex formation between the vaccine and TLR4 were predicted.
- In silico simulations indicated the potential to induce a robust immune response, including IL-4 and IL-10 production.
Conclusions:
- The rationally designed SART3-targeted multi-epitope vaccine exhibits promising in silico characteristics.
- The vaccine's profile across immunogenicity, physicochemical properties, and structural integrity supports its potential in cancer immunotherapy.
- Experimental validation is warranted to confirm these in silico findings and advance vaccine development.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...